THE COST-EFFECTIVENESS OF SEQUENTIAL FIRST- AND SECOND-LINE TREATMENTS IN METASTATIC RENAL CELL CARCINOMA USING REAL-WORLD DATA AND A PATIENT-LEVEL SIMULATION MODEL

被引：0
|
作者：
de Groot, S. [1 ]
Blommestein, H. [1 ]
Redekop, W. [1 ]
Oosterwijk, E. [2 ]
Kiemeney, L. [2 ]
Uyl-de Groot, C. [1 ]
机构：
[1] Erasmus Univ, Rotterdam, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.1625
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A587 / A587
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC)
    Goldstein, Daniel A.
    Chen, Qiushi
    Howard, David H.
    Lipscomb, Joseph
    Ayer, Turgay
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] CLINICAL EFFECTIVENESS AND COST-EFFECTIVE SECOND-LINE TREATMENT FOR METASTATIC RENAL CELL CARCINOMA
    Romero, M.
    Diaz, E.
    Malagon, J.
    VALUE IN HEALTH, 2011, 14 (07) : A543 - A543
  • [23] Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization
    Lu, Brandon
    Dai, Wei Fang
    Croxford, Ruth
    Isaranuwatchai, Wanrudee
    Beca, Jaclyn
    Menjak, Ines B.
    Petrella, Teresa M.
    Mittmann, Nicole
    Earle, Craig C.
    Gavura, Scott
    Mercer, Rebecca E.
    Hanna, Timothy P.
    Chan, Kelvin K. W.
    CANCER MEDICINE, 2023, 12 (10): : 11451 - 11461
  • [24] Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study
    Wells, J. Connor
    Dudani, Shaan
    Gan, Chun Loo
    Stukalin, Igor
    Azad, Arun A.
    Liow, Elizabeth
    Donskov, Frede
    Yuasa, Takeshi
    Pal, Sumanta K.
    De Velasco, Guillermo
    Hansen, Aaron R.
    Beuselinck, Benoit
    Kollmannsberger, Christian K.
    Powles, Thomas
    McGregor, Bradley A.
    Duh, Mei S.
    Huynh, Lynn
    Heng, Daniel Y. C.
    CLINICAL GENITOURINARY CANCER, 2021, 19 (04) : 354 - 361
  • [25] Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India
    Gupta, Dharna
    Singh, Ashish
    Gupta, Nidhi
    Mehra, Nikita
    Bahuguna, Pankaj
    Aggarwal, Vipul
    Krishnamurthy, Manjunath Nookala
    Roy, Partha Sarathi
    Malhotra, Pankaj
    Gupta, Sudeep
    Kumar, Lalit
    Kataki, Amal
    Prinja, Shankar
    JCO GLOBAL ONCOLOGY, 2023, 9 : e2200246
  • [26] COST-EFFECTIVENESS OF BENDAMUSTINE-RITUXIMAB IN FIRST-LINE INDOLENT NHL: A PATIENT-LEVEL SIMULATION
    Dewilde, S.
    Woods, B.
    Castaigne, J. G.
    Parker, C.
    Dunlop, W.
    VALUE IN HEALTH, 2013, 16 (07) : A415 - A415
  • [27] Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study
    Zhang, Haoran
    Chen, Junru
    Zhang, Xingming
    Zhu, Xudong
    Wang, Zilin
    Sun, Guangxi
    Liang, Jiayu
    Chen, Yuntian
    Shen, Yali
    Liu, Jiyan
    Li, Xiang
    Wei, Qiang
    Liu, Zhenhua
    Zeng, Hao
    Shen, Pengfei
    IMMUNOTHERAPY, 2022, 14 (05) : 309 - 320
  • [28] Real-world experience of axitinib as second-line treatment in metastatic renal cell carcinoma: Analysis of the Swedish population.
    Strambi, Angela
    Jakobsson, Maria
    Nilsson, Fredrik
    Arpegard, Johannes
    Dalen, Johan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [29] ERLOTINIB VS DOCETAXEL AS SECOND-LINE TREATMENT OF ADVANCED NSCLC: A REAL-WORLD COST-EFFECTIVENESS STUDY
    Cromwell, Ian
    Van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1181 - S1182
  • [30] COST-EFFECTIVENESS OF SEQUENTIAL TREATMENT STRATEGIES WITH TNFINHIBITORS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: A PATIENT-LEVEL SIMULATION MODEL
    Le, Q.
    Kang, J.
    Lee, S.
    VALUE IN HEALTH, 2018, 21 : S198 - S198
12345